Tag: percent-or-more

By Lewis Krauskopf NEW YORK (Reuters) – Eli Lilly & Co’s massive setback for its experimental Alzheimer’s disease treatment on Wednesday sent investors scrambling to re-evaluate shares of the U.S. drugmaker and those of companies making competing therapies, including biotech stalwart Biogen Inc. Lilly shares tumbled 10.5 percent, and fell to their lowest point in…